Sandoz Introduces Tyruko (Biosimilar, Tysabri) for Multiple Sclerosis in Germany
Shots:
- Sandoz has introduced Tyruko (natalizumab), biosimilar of Tysabri for the treatment of r/r multiple sclerosis (RRMS), in Germany which will be available from Feb 1
- Polpharma Biologics is responsible for the development, manufacturing and supply of Tyruko while Sandoz holds its commercialization rights in all markets as per a global commercialization agreement signed between them in 2019
- Tyruko is an anti-α4 integrin mAb indicated as a single disease-modifying therapy (DMT) for treating adults with highly active RRMS
Ref: Sandoz | Image: Sandoz
Related News:- Sandoz’ Tyruko (biosimilar, natalizumab) Receives the US FDA’s Approval as First Biosimilar for Relapsing Forms of Multiple Sclerosis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
